874482-94-7

Upstream product

• 1006904-72-8 silver(I) trifluoromethoxide 
• 20925-27-3 4-amino-2-chlorobenzonitrile 
• 557-21-1 zinc(II) cyanide 
• 653578-64-4 2-chloro-4-(trifluoromethoxy)phenyltrifluoromethane sulfonate 
• 70783-75-4 4-(trifluoromethoxy)-2-chlorophenol 
• 773837-37-9 sodium cyanide 
• 69695-61-0 2-chloro-4-(trifluoromethoxy)aniline 
• 557-21-1 dicyanozinc 

Downstream Products

• 1079351-20-4 2-chloro-4-trifluoromethoxybenzaldehyde 
• 874571-72-9 1-[2-chloro-4-(trifluoromethoxy)phenyl]methanamine 

Relevant academic research and scientific papers

Silver-Mediated Trifluoromethoxylation of (Hetero)aryldiazonium Tetrafluoroborates

Here we report a silver-mediated trifluoromethoxylation of (hetero)aryldiazonium tetrafluoroborates by converting an aromatic amino group into an OCF3 group. This method, which can be considered to be a trifluoromethoxylation variation of the classic Sandmeyer-type reaction, uses readily available aryl and heteroaromatic amines as starting materials and AgOCF3 as trifluoromethoxylating reagents. The broad substrate scope and simple, mild reaction condition made this transformation a valuable method in constructing aryl-OCF3 bonds.

ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS

Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the c

INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Formula (I). Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).

BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

BICYCLIC HETEROCYCLIC COMPOUND

In the prevention and/or treatment of a neuropsychiatric disease or a peripheral organ disease and the like, a pharmaceutical which comprises a compound having CRF antagonistic activity as an active ingredient is provided. A compound of a formula (I): wherein R1 represents a C3-10 branched alkyl group which may be substituted; R2 represents a hydrogen atom or a C1-4 alkyl group which may be substituted; R3 represents a C1-4 alkyl group which may be substituted or a halogen atom; R4 represents a C1-4 alkyl group which may be substituted; and ring 1 represents a cyclic group which has planarity and may have a substituent group, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof, is useful as a medicinal component having CRF antagonistic activity for the prevention and/or treatment of a neuropsychiatric disease, a peripheral organ disease and the like.

SUBSTITUTED QUINOLONES III

The invention relates to substituted quinolones and to methods for their preparation as well as to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.

Substituted quinolones II

The invention relates to substituted quinolones of formula (I) and to methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particu

SUBSTITUTED QUINOLONES

The invention relates to substituted quinolones methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular, for use as antiviral agents, in particular, against cytomegaloviruses.